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Women living in Latin American countries bear a disproportionate burden of cervical cancer, a condition caused by infection with
the human papillomavirus (HPV). We performed a study in Santa Elena, Guayas (currently Santa Elena Province), Ecuador, to
determine how often HPV could be detected in women attending a private cancer screening clinic. Participants underwent a Pap
test, and vaginal and cervical swabs were performed for HPV testing by the polymerase chain reaction (PCR). Each participant
completed a verbally administered survey. The mean age of 302 participants was 37.7 years (range 18 to 78 years). The majority
of cervical and vaginal specimens contained sufficient DNA to perform PCR. Overall, 24.2% of the participants had either a
cervical or vaginal swab that tested positive for HPV. In general, there was a good correlation between the HPV types detected
in the cervical and vaginal swabs from the participants, but vaginal swabs were more likely to contain HPV DNA than were
cervical swabs. The high-risk HPV types 16, 52, 58, and 59 and the low-risk HPV types 62, 71, 72, and 83 were the most
frequently detected HPV types. The number of lifetime sexual partners was positively associated with detection of any HPV type,
detection of oncogenic HPV, and abnormal Pap smears. Further studies are needed to determine if these results are
representative of all Ecuadorian women and to determine if cervical cancers in Ecuadorian women are caused by the same HPV
types found in the swab specimens obtained in this study.
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Introduction
Human papillomavirus (HPV), the causative agent of
cervical cancer, is the most common sexually transmitted
infection. In addition to cervical cancer, HPV-related malig-
nancies include vulvar cancer (1), vaginal cancer and anal
cancer (2). Furthermore, approximately 45% of cases of
penile cancer are associated with HPV (3). Of the approxi-
mately 100 different types of HPVs that have been identi-
fied and fully sequenced, approximately 40 infect the geni-
tal tract (4,5). The most common type of HPV associated
with non-cervical genital tract cancers is HPV 16, which
causes more than 50% of these cancers (3,6).
The genital HPV types are divided into two categories,
‘high risk’ and ‘low risk’, originally assigned based on whether
the HPV type could or could not be found as a solitary isolate
in cervical cancer specimens. Individuals infected with high-
risk HPV infection have an increased risk of cervical cancer.
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High-risk types such as HPV types 16, 18 and related HPV
types cause dysplastic lesions of the cervix (manifested by
abnormal Pap smears), which may progress to invasive
cancer of the cervix in a subset of infected women (7).
Women infected with only low-risk HPV types have a low risk
of developing cervical cancer. The low-risk types such as
HPV 6 and HPV 11 are associated with benign, proliferative
lesions known as condylomata acuminata, and commonly
referred to as genital warts (8-10). Because HPV is the
causative agent of cervical cancer, knowledge of the epide-
miology of HPV is critical.
Cervical cancer is caused by HPV infection, with ap-
proximately 500,000 overall cases of cervical cancer and
about 275,000 deaths worldwide every year (11-14). Women
in Latin American countries bear a disproportionate burden
of cervical cancer (15). Rates of cervical cancer are approxi-
mately 30 per 100,000 in Ecuador, Venezuela, and Mexico
in women aged 35 through 64 years, and rates are higher
than 20 per 100,000 in several other Latin American coun-
tries (16). These rates far exceed those in the United States
and Canada (approximately 4 per 100,000), and cervical
cancer mortality in Latin American women is at least 4-fold
higher than in the United States (15,17).
Few studies have examined the epidemiology of HPV
in Ecuador, a country in which routine Pap smears are
generally not done, and a country with a high cervical
cancer death rate (15,18,19). We therefore performed a
study in Santa Elena, Guayas, Ecuador, to determine how
often HPV could be detected in women attending a private
cancer screening clinic. We compared HPV detection in
vaginal swabs and cervical swabs, and determined the
types of HPV that were detected in these women. We also




Female patients older than 18 years presenting to the
Society for the Fight Against Cancer (SOLCA for its abbre-
viation in Spanish), a private cancer screening clinic in
Santa Elena, Guayas, Ecuador, were asked to participate
in the study. Approval of the Institutional Review Board at
Indiana University School of Medicine was obtained for the
study, as well as approval of officials of SOLCA. To be
included, a subject had to be at least 18 years of age with
an intact uterus, have a history of sexual intercourse with a
male partner, and be able to provide informed consent.
Subjects were enrolled between September 2005 and
January 2006. Subjects with clinical evidence of gross
cervicitis were excluded, as were individuals who were
menstruating at the time of their visit. Written consent was
obtained from each subject prior to her enrollment in the
study. A copy of the signed consent form was given to the
participant.
Survey
Each participant was asked to complete a short survey
that was verbally administered. Specific questions were
asked regarding age, marital status, the number of lifetime
sexual partners, pregnancies, previous Pap smears, pre-
vious diagnosis of genital warts, and cigarette smoking.
Procedures
All participants underwent routine clinical procedures
including history and physical exam. A Pap test, vaginal
swab, and a cervical swab were obtained from all partici-
pants. The Pap test was performed by local clinicians
using an Ayres spatula and a cytobrush to assess for
abnormalities in the exfoliated cervical cells, and was
interpreted at the SOLCA clinic. Participants with abnor-
mal cytology results were treated according to the SOLCA
clinic standard of care. Pap smears were also examined at
a later time by a cytology technician at the Indiana Univer-
sity School of Medicine; no patient identification was pro-
vided to Indiana University. Examination of Pap smears at
Indiana University was done solely for educational pur-
poses, and had no bearing on patient care. No specific
quality control of locally interpreted Pap smears was done.
For the endo/ectocervical specimen, a Pap smear was
performed using an Ayers spatula, then the vaginal specu-
lum was left in place. A DACRON™ swab was introduced
into the cervical os with enough pressure to maintain
contact with the epithelium but not to induce bleeding. The
swab was twirled one to two times, and then back and forth
across the ectocervix. The swab was then placed in the
collection tube, the end of the shaft protruding from the
tube was broken off, and the tube was sealed with the cap.
The capped plastic tube was labeled with a number only
and stored at -20°C until ready for shipment. For the
vaginal specimen, the DACRON™ swab was introduced
into the vaginal vault, and moved back and forth in a zigzag
motion along both lateral walls. The swab was then placed
into the collection tube, and processed as for the cervical
swab. The cervical/vaginal specimens were sent by DHL
to the Indiana University School of Medicine.
HPV detection
The Roche polymerase chain reaction (PCR)/reverse
blot strip assay was used for HPV typing (20). This assay
uses a set of oligonucleotide primer pools PGMY09 and
PGMY11 based on the same primer binding regions used
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for the MY09/11 degenerate primer PCR assay. Reactions
were amplified in a Perkin Elmer TC9600 Thermal Cycler
(Perkin Elmer Corp., USA) as previously described (21).
Known positive and negative (no DNA) specimens were
included in each assay as controls. To determine speci-
men adequacy, the GH20/PC04 human β-globin gene
target was co-amplified with HPV sequences. The HPV
immobilized probe array used to determine HPV type
contains probe lines to detect individual HPV types and
human β-globin control probes. High-risk HPV types de-
tected in the assay are 16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 67, 68, 70, 73, 82, and IS39 (a partially
characterized type). Low-risk types detected in the assay
are 6, 11, 40, 42, 54, 55, 61, 62, 64, 71, 72, 81, 83, 84, and
CP (a partially characterized type). Hybridization and de-
tection were performed as described by the manufacturer
(Roche Molecular Diagnostics, USA).
Data analysis
Subject characteristics, including age, marital status,
the number of lifetime sexual partners, pregnancies, previ-
ous Pap smears, previous diagnosis of genital warts, and
cigarette smoking were summarized. Relative frequencies
of HPV infections, including both high-risk and low-risk
types, were described graphically by a bar chart. Type-
specific HPV detections in cervical and vaginal specimens
were presented graphically. HPV test results were then
cross-tabulated by sample collection methods (cervical
and vaginal swabs) and Pap smear results [Normal, low-
grade squamous intraepithelial lesions (LGSIL), and high-
grade squamous intraepithelial lesions (HGSIL)]. Age-
specific prevalence rates of high-risk and any HPV infec-
tions were also reported. Logistic regression analyses
were performed to identify correlates of high-risk HPV, any
HPV infection, and abnormal Pap smear.
Results
Demographics and clinical characteristics of study
participants
A total of 311 women completed the survey and partici-
pated in the study, including Pap smear testing and speci-
men collection. Overall, we included 302 (97.1%) of all
participants in the analysis for HPV, as these participants
had both cervical and vaginal specimens that were positive
for β-globin, and therefore had adequate specimens for HPV
analysis, and had a Pap smear performed. No participant
experienced an adverse event as a result of the study.
The mean age of these 302 participants was 37.7 years
(range 18 to 78 years). For marital status, 263 (88.3%)
were married or in a common law union, 35 (11.7%) were
single or widowed, and four participants gave no response
to this question. The mean age (± SD) of first sexual
intercourse was 18.1 ± 3.8 years.
The mean number of lifetime sex partners was 1.7 ±
1.4; 181 participants (61.4%) reported 1 lifetime sex part-
ner, 73 (24.8%) reported 2 lifetime sex partners, 21 (7.1%)
reported 3 lifetime sex partners, 5 participants (1.7%)
reported 4 lifetime partners, and 15 participants (5.0%)
reported 5 or more lifetime sex partners. Seven partici-
pants did not answer this question.
The mean number of pregnancies for the participants
was 4.3 ± 3.1, with a range of zero to 15 pregnancies. Pap
smears had been previously performed on 235, or 77.8%
of study participants. A history of an abnormal Pap smear
was reported by 17 (5.6%) participants. A history of genital
warts was reported by 26 (8.6%) participants. Nineteen
participants (6.3%) smoked cigarettes.
HPV detection in all study participants
Of all specimens collected, 99.0% of the cervical and
98.0% of the vaginal specimens contained sufficient DNA to
perform PCR, based on amplification of the human β-globin
gene. As indicated above, a total of 302 participants had
adequate specimens from both the cervix and vagina, and
had Pap smears performed. Women among these 302
participants were considered to be positive for HPV if either
the cervical or vaginal swab was positive for HPV. Overall,
73 women, or 24.2% of all participants tested positive for
HPV (Table 1). High-risk HPV types were detected in 44
women (14.6%). The most frequently detected high-risk
HPV types were HPV 16, 52, 58, and 59 (Figure 1).
Low-risk HPV types were detected in one or both swab
specimens from 44 women (14.6%). The most frequently
detected low-risk HPV types were HPV types 62, 71, 72,
and 83 (Figure 1). Both high- and low-risk HPV types were
detected in 15 women (5.0%). A mean of 1.4 different HPV
types was detected in each HPV-positive woman.
HPV detection according to type of swab
In addition to considering rates of HPV detection in the
study participants, we also considered the frequency of
HPV detection in vaginal and cervical swabs (Table 1).
This was done to determine if vaginal swabs (which women
can perform without supervision from a doctor or nurse)
and cervical swabs (which must be done by a clinician)
would provide the same or similar HPV type distribution.
Of the cervical swabs from the 302 participants, 43, or
14.2% were positive for any HPV (Table 1). Thirty-one
cervical swabs, or 10.3%, were positive for 1 or more high-
risk HPV types, and 15 cervical swabs, or 5.0% were
positive for 1 or more low-risk HPV types. Of 302 vaginal
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Figure 1. Detection of specific human papillomavirus (HPV) types in 302 participants. The percent of each HPV type detected is
indicated on the y-axis and the specific HPV types that have been detected are indicated on the x-axis. A woman was considered to
be infected with an HPV type if either the cervical or vaginal swab contained that HPV type.
Table 1. Detection of human papillomavirus (HPV) in cervical and vaginal swabs and in participants.
Any HPV HR-HPV LR-HPV HR-HPV + LR-HPV
Cervical swabs (N = 302) 43 (14.2%) 31 (10.3%) 15 (5.0%) 3 (1.0%)
Vaginal swabs (N = 302) 55 (18.2%) 36 (11.9%) 43 (14.2%) 12 (4.0%)
Participants (N = 302) 73 (24.2%) 44 (14.6%) 44 (14.6%) 15 (5.0%)
Data are reported as number with percent in parentheses. HR-HPV = high-risk or oncogenic HPV; LR-HPV = low-risk or non-
oncogenic HPV.
swabs, 55 (18.2%) were positive for any HPV, 36 swabs
(11.9%) were positive for 1 or more high-risk HPV types,
and 43 vaginal swabs (14.2%) were positive for 1 or more
low-risk HPV types (Table 1).
There were many different HPV types detected in both
types of swabs (Figure 2). The most frequently detected
high-risk HPV types in cervical swabs were HPV types 16
(7 cases), 59 (5 cases), 31, 39, 58 (4 cases each), and 52
(3 cases). The most frequently detected low-risk HPV
types in cervical swabs were HPV types 71 (8 cases) and
62 (4 cases).
The most frequently detected high-risk HPV types in
vaginal swabs were HPV types 16 and 39 (6 cases each),
52 and 59 (5 cases each), and 53 and 58 (4 cases each).
The most frequently detected low-risk HPV types in vagi-
nal swabs were HPV types 71 and 83 (9 cases each), 72 (8
cases), and 62 (7 cases).
In general, there was a good correlation between the
HPV types detected in the cervical and vaginal swabs from
the participants. However, several types such as HPV
types 72 and 83 were more frequently detected in vaginal
swabs than in cervical swabs (Figure 2).
Pap smear results and HPV detection
Of all study participants, 285 (94.4%) had normal Pap
smears, and 17 (5.6%) had abnormal Pap smears (Table
2). Of the 17 abnormal Pap smears, 13 were LGSIL and 4
were HGSIL. The diagnosis of atypical squamous cells of
undetermined significance (ASCUS) was not made for any
of the participants. This observation may have been a
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feature of local cytologic interpretation, since some of the
LGSIL specimens (local interpretation) were interpreted as
ASCUS by cytologists at Indiana University.
Of the 285 participants with normal Pap smears, 59
(20.6%) were HPV-positive, and 31 (10.9%) were high-risk
HPV-positive. Of the 13 participants with Pap smears
indicating LGSIL, 10 (76.9%) were positive for HPV, and
high-risk HPV types were detected in 9 (69.2%) of these 13
women. All 4 participants with Pap smears indicating an
HGSIL were positive for HPV in 1 or both swabs, and high-
risk HPV types were detected in all 4 of these women.
Both HPV positivity (P < 0.0001) and high-risk HPV
positivity (P < 0.0001) were associated with Pap smear
abnormality. Lifetime number of sexual partners was
strongly associated with abnormal Pap smear results (P =
0.0064). Specifically, the odds of having an abnormal Pap
smear increased by approximately 60% for each added
Table 2. Association of Pap smear results with human papillo-
mavirus (HPV) detection.
Normal LGSIL HGSIL
Number of participants 285 13 4
Any HPV-positive 59 (20.7%) 10 (76.9%) 4 (100%)
HR-HPV-positive 31 (10.9%) 9 (69.2%) 4 (100%)
Data are reported as number with percent in parentheses. LGSIL
= low-grade squamous intraepithelial lesions; HGSIL = high-
grade squamous intraepithelial lesions; HR-HPV = high-risk or
oncogenic HPV.
Figure 2. Detection of specific human papillomavirus (HPV) types in cervical and vaginal swab specimens from 302 women. The
percent of each HPV detected in the swabs is indicated on the y-axis and the specific HPV types detected in the assay are shown on
the x-axis.
Table 3. Association of age with human papillomavirus (HPV) detection.
0 to 20 years 21 to 30 years 31 to 40 years 41 to 50 years 51 years and older
Number of participants 8 92 89 69 43
Any HPV-positive 3 (37.5%) 20 (21.7%) 20 (22.5%) 16 (23.2%) 12 (27.9%)
HR-HPV-positive 3 (37.5%) 9 (9.8%) 9 (10.1%) 12 (17.4%) 9 (20.9%)
Data are reported as number with percent in parentheses. Two participants did not provide age. HR-HPV = high-risk or oncogenic HPV.
sexual partner (odds ratio estimate 1.6; 95%CI = 1.1-2.2).
These observations from Ecuador are consistent with stud-
ies of HPV detection and abnormal cervical cytology, and
with previous studies conducted elsewhere that indicate
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an increased chance of HPV infection in women with many
lifetime sexual partners (6,14).
As shown in Table 3, there was a modest increase in
HPV and high-risk HPV detection in older women (51
years of age and older), consistent with previous studies of
HPV epidemiology in Latin American women (22,23). The
number of pregnancies, a history of genital warts, smoking
cigarettes, and marital status were not factors associated
with HPV positivity, high-risk HPV positivity, or abnormal
Pap smears.
Discussion
The aims of our study were to contribute to the knowl-
edge of HPV prevalence and type distribution in a defined
population of Ecuadorian women, and to evaluate the
utility of vaginal swab specimens in these women. We
sought to determine how often women attending a cervical
cancer screening clinic in Santa Elena, Ecuador, had
demonstrable HPV and abnormal cervical cytology. In
addition, we examined several factors associated with the
detection of HPV including age, number of lifetime sex
partners, and Pap smear abnormalities. We found that the
number of lifetime sexual partners was positively associ-
ated with detection of HPV and with abnormal pap smears.
Cervical cancer is caused by persistent infection with
oncogenic HPV (24,25). A better understanding of the
natural history of HPV infection in women living in Ecuador
is needed because cervical cancer is very common in this
country. Many women in Ecuador do not undergo routine
cervical cancer screening and cancer is often not detected
until the late stages of disease. Routine cervical cancer
screening is not always available to women in Ecuador
and other countries due to economic and logistic obstacles
(26).
The physicians who performed the survey, Pap smear,
and HPV cervical and vaginal swabs were Ecuadorian
gynecologists, and therefore the level of communication
between the study participants and examiners was not
compromised due to language or cultural barriers. Additi-
onally, approximately 25% of the women enrolled in the
study had never had a prior Pap smear. Having this first
exam will potentially reduce the stigma of having gyneco-
logic screening for these patients and the larger female
community in the city. Also, although the Dacron swabs
used for HPV testing were shipped over a large distance,
adequate DNA was obtained from approximately 98% of
the specimens, demonstrating that shipping did not greatly
decrease the utility of the swabs.
Detection methods for HPV include hybrid capture and
PCR (27). The hybrid capture assay uses pooled probes to
detect HPV in specimens, provides no specific HPV type
information, and cannot determine whether individual or
multiple types are present. In addition, it is an expensive
assay (approximately US$60 per assay). PCR assays are
used primarily in research involving HPV. PCR assays
provide type-specific information, but are technically diffi-
cult and expensive.
This study has some limitations. Due to selection bias,
the conclusions may not be applicable to the general
population of Ecuadorian women. In particular, it is pos-
sible that our study underestimated the true prevalence of
HPV infection in the community as a whole. The women
who participated in this study were self-selected, as they
presented themselves to the clinic for cancer screening or
for gynecologic care. In order to self-present, therefore, a
number of prerequisites had to have been met. Primarily,
women had to know about the existence of the clinic (it
opened approximately 9 months before the start of enroll-
ment) and had to be aware of and be interested in gyneco-
logic care. Nearly 75% of participants in our study had
received a Pap smear previously. Thus, these women
clearly had knowledge of the importance of Pap smears
and also possessed the means to pay for the test (which
was ultimately paid for by the study). It is possible that
many women in the city of Santa Elena either did not know
about the clinic’s existence, the role of gynecologic care
apart from obstetrical intervention during pregnancy and
parturition, or that the clinic offered gynecologic cancer
screening. Additionally, the women who did know about
the clinic and were interested in gynecologic care must
have had transportation to the clinic. The major mode of
transportation within the city of Santa Elena is ambulation,
and some “barrios” are 2 to 3 km from the clinic site.
Therefore, we may have unintentionally excluded those
women who were sicker or disabled in some way, and
potentially therefore excluded women with symptomatic
invasive cervical cancer. Finally, the major mode of infor-
mation transmission in Santa Elena is by word-of-mouth,
especially regarding health information. Therefore, it is
possible that many women living in the outlying “barrios”
did not know about the enrollment period of the study.
Women in Ecuador suffer from a high cervical cancer
burden. Larger studies are needed to classify the high-risk
HPV types that are most prevalent in the country, and to
determine which HPV types are most associated with
actual invasive cancer tissues. The present study demon-
strated the expected association between high-risk HPV
types and cervical dysplasia in this specific population. For
improved prevention of HPV transmission and treatment of
HPV-related lesions, access to screening and treatment
must be improved. Ecuador ranks 110th of 174 listed
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countries for gross domestic product per capita, and many
women have little to spend on their own health care (28).
Many women do not go to a gynecologist unless symptoms
such as vaginal bleeding are present, and often not unless
these symptoms have been present for a long time, in
order to avoid incurring a health-care cost.
How can the burden of cervical dysplasia and cancer
be reduced in Ecuador and other Latin American countries
with limited resources? Behavioral measures including
delaying sexual intercourse, the regular use of latex
condoms, which has been shown to reduce the transmis-
sion of HPV (29,30), and limiting the number of lifetime
sexual partners may all be of benefit. Because of the
barriers to Pap smear screening and treatment of precan-
cerous lesions, the HPV vaccine might be an ideal way to
protect women in Ecuador from invasive cervical cancer.
Currently, the cost of the vaccine is all but prohibitive for
these women, who are at high risk due to their reduced
access to screening. Therefore, we urge the manufactur-
ers of the newly approved HPV vaccines to provide vac-
cine free of charge or at a reduced cost to the women of
Ecuador, thus making this mode of prevention accessible
to those women who most need it. Our data may serve to
encourage new and larger studies to determine the preva-
lence of HPV in the general population of Ecuadorian
women who do not necessarily have access to cervical
cancer screening.
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